Abstract
SARS-CoV-2 vaccines, administered to billions of people worldwide, mitigate the effects of the COVID-19 pandemic, however little is known about the molecular basis of antibody cross-protection to emerging variants, such as Omicron BA.1, its sublineage BA.2, and other coronaviruses. To answer this question, 276 neutralizing monoclonal antibodies (nAbs), previously isolated from seronegative and seropositive donors vaccinated with BNT162b2 mRNA vaccine, were tested for neutralization against the Omicron BA.1 and BA.2 variants, and SARS-CoV-1 virus. Only 14.2, 19.9 and 4.0% of tested antibodies neutralize BA.1, BA.2, and SARS-CoV-1 respectively. These nAbs recognize mainly the SARS-CoV-2 receptor binding domain (RBD) and target Class 3 and Class 4 epitope regions on the SARS-CoV-2 spike protein. Interestingly, around 50% of BA.2 nAbs did not neutralize BA.1 and among these, several targeted the NTD. Cross-protective antibodies derive from a variety of germlines, the most frequents of which were the IGHV1-58;IGHJ3-1, IGHV2-5;IGHJ4-1 and IGHV1-69;IGHV4-1. Only 15.6, 20.3 and 7.8% of predominant gene-derived nAbs elicited against the original Wuhan virus cross-neutralize Omicron BA.1, BA.2 and SARS-CoV-1 respectively. Our data provide evidence, at molecular level, of the presence of cross-neutralizing antibodies induced by vaccination and map conserved epitopes on the S protein that can inform vaccine design.
【초록키워드】 SARS-CoV-2, vaccination, cross-protection, Vaccines, S protein, Neutralizing antibodies, antibody, mRNA vaccine, neutralization, COVID-19 pandemic, Vaccine design, SARS-CoV-2 vaccines, omicron, virus, SARS-CoV-1, variants, Spike protein, Receptor binding domain, BNT162b2, Epitopes, Region, cross-neutralizing antibody, RBD, SARS-CoV-2 spike protein, Wuhan, NTD, molecular, epitope, seropositive, seronegative, neutralizing monoclonal antibodies, neutralizing monoclonal antibody, BNT162b2 mRNA vaccine, NAb, Donor, cross-neutralize, Evidence, other coronaviruses, NAbs, molecular basis, class, cross-neutralizing antibodies, Administered, Effect, mitigate, neutralize, germlines, IGHV1-58, IGHV1-69, IGHV2-5, SARS-CoV-1 virus, tested, conserved, question, recognize, variety, the S protein, predominant, elicited, not neutralize, the SARS-CoV-2, 【제목키워드】 COVID-19, neutralizing antibody, omicron, mRNA, vaccinee,